Movement Alert｜Veeva Rises 8.61% Overnight, Q2 Earnings and Full-Year Guidance Beat Expectations Across the Board

Market Focus

Aug 27

On August 27, Veeva rose 8.61% overnight, trading at $266.0/share, with turnover of $2,927.9.

The company reported fiscal Q2 adjusted EPS of $2.35, beating the consensus estimate of $2.22 by approximately 5.86% and representing an 18.09% year-over-year increase. Revenue came in at $928 million, surpassing the $905 million estimate. For fiscal Q3, the company guided adjusted EPS of $2.33–$2.34 on revenue of $932–$935 million, both above analyst expectations of $2.28 and $918 million respectively. Full-year fiscal 2027 adjusted EPS guidance was raised to approximately $9.21, exceeding the Street estimate of $9.06.

Ahead of earnings, the company secured Biogen, Regeneron, and Eli Lilly as global Vault CRM clients, bringing commitments from 13 of the top 20 pharmaceutical companies and reinforcing its dominant position in life sciences CRM. Guggenheim and Stifel raised price targets to $276 and $275 respectively, maintaining Buy ratings.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/1100789947"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1100789947\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1100789947?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-27 08:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1100789947","market":"us","top_or_hot":-1,"title":"Movement Alert｜Veeva Rises 8.61% Overnight, Q2 Earnings and Full-Year Guidance Beat Expectations Across the Board","media":"Market Focus","content":"<p><p>On August 27, Veeva rose 8.61% overnight, trading at $266.0/share, with turnover of $2,927.9.</p><p>The company reported fiscal Q2 adjusted EPS of $2.35, beating the consensus estimate of $2.22 by approximately 5.86% and representing an 18.09% year-over-year increase. Revenue came in at $928 million, surpassing the $905 million estimate. For fiscal Q3, the company guided adjusted EPS of $2.33–$2.34 on revenue of $932–$935 million, both above analyst expectations of $2.28 and $918 million respectively. Full-year fiscal 2027 adjusted EPS guidance was raised to approximately $9.21, exceeding the Street estimate of $9.06.</p><p>Ahead of earnings, the company secured Biogen, Regeneron, and Eli Lilly as global Vault CRM clients, bringing commitments from 13 of the top 20 pharmaceutical companies and reinforcing its dominant position in life sciences CRM. Guggenheim and Stifel raised price targets to $276 and $275 respectively, maintaining Buy ratings.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Veeva Rises 8.61% Overnight, Q2 Earnings and Full-Year Guidance Beat Expectations Across the Board</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Veeva Rises 8.61% Overnight, Q2 Earnings and Full-Year Guidance Beat Expectations Across the Board\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-27 08:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 27, Veeva rose 8.61% overnight, trading at $266.0/share, with turnover of $2,927.9.</p><p>The company reported fiscal Q2 adjusted EPS of $2.35, beating the consensus estimate of $2.22 by approximately 5.86% and representing an 18.09% year-over-year increase. Revenue came in at $928 million, surpassing the $905 million estimate. For fiscal Q3, the company guided adjusted EPS of $2.33–$2.34 on revenue of $932–$935 million, both above analyst expectations of $2.28 and $918 million respectively. Full-year fiscal 2027 adjusted EPS guidance was raised to approximately $9.21, exceeding the Street estimate of $9.06.</p><p>Ahead of earnings, the company secured Biogen, Regeneron, and Eli Lilly as global Vault CRM clients, bringing commitments from 13 of the top 20 pharmaceutical companies and reinforcing its dominant position in life sciences CRM. Guggenheim and Stifel raised price targets to $276 and $275 respectively, maintaining Buy ratings.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VEEV","symbol_name":"Veeva Systems Inc.","start_time":0,"source_url":"","article_id":"1100789947","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1100789947","pubTimestamp":1787789347,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 27, Veeva rose 8.61% overnight, trading at $266.0/share, with turnover of $2,927.9.The company reported fiscal Q2 adjusted EPS of $2.35, beating the consensus estimate of $2.22 by...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VEEV":"Veeva Systems Inc."},"translate_title":"走势警报|Veeva隔夜上涨8.61%，第二季度盈利和全年指引全面超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VEEV":1},"content_text":"On August 27, Veeva rose 8.61% overnight, trading at $266.0/share, with turnover of $2,927.9.The company reported fiscal Q2 adjusted EPS of $2.35, beating the consensus estimate of $2.22 by approximately 5.86% and representing an 18.09% year-over-year increase. Revenue came in at $928 million, surpassing the $905 million estimate. For fiscal Q3, the company guided adjusted EPS of $2.33–$2.34 on revenue of $932–$935 million, both above analyst expectations of $2.28 and $918 million respectively. Full-year fiscal 2027 adjusted EPS guidance was raised to approximately $9.21, exceeding the Street estimate of $9.06.Ahead of earnings, the company secured Biogen, Regeneron, and Eli Lilly as global Vault CRM clients, bringing commitments from 13 of the top 20 pharmaceutical companies and reinforcing its dominant position in life sciences CRM. Guggenheim and Stifel raised price targets to $276 and $275 respectively, maintaining Buy ratings.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}